TTR and Alzheimer disease: The level of transthyretin protein was increased in the PS1P117L AD neurons by rhTFAM treatment (Fig. 5c), without increasing its mRNA level, suggesting that reduced ROS generation by rhTFAM results in suppression of oxidative modification of transthyretin and its stabilization.